Literature DB >> 7654478

Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.

T A Aasmundstad1, B Q Xu, I Johansson, A Ripel, A Bjørneboe, A S Christophersen, E Bodd, J Mørland.   

Abstract

1. The pharmacokinetics of ethylmorphine after administration of a single dose of the cough mixture Cosylan were investigated in 10 healthy subjects. 2. The median urinary recovery of ethylmorphine and measured metabolites was 77% over 48 h. The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h. Ethylmorphine-6-glucuronide was found to be the major metabolite. 3. Two subjects had significantly lower urinary recovery (0.48 h) of morphine and morphine-glucuronides than the remainder. Furthermore, these two had urinary metabolic ratios (MRO) and partial metabolic clearances (CLmO) for O-deethylation of ethylmorphine tentatively classifying them phenotypically as poor metabolisers of the debrisoquine/sparteine type. 4. Genotyping for cytochrome P450 (CYP) 2D6 alleles revealed five homozygote (wt/wt) and five heterozygote subjects. Two subjects phenotypically classified as poor metabolisers were genotypically CYP2D6A/wt and CYP2D6D/wt, respectively. 5. Serum and urine samples taken more than 8 and 24 h after administration of ethyl-morphine respectively, contained morphine and morphine-glucuronides, but no ethylmorphine, ethylmorphine-6-glucuronide or (serum only) norethylmorphine. Norethylmorphine could be detected after hydrolysis of urine samples in all subjects. The urinary recovery of the active metabolites morphine and morphine-6-glucuronide after administration of ethylmorphine varied by a factor of 9 between individuals. 6. The wide variation in recovery of morphine and morphine-glucuronides after oral administration of ethylmorphine could not be explained simply by a difference in CYP2D6 genotype. Constitutional variation in other enzymatic pathways involved in ethylmorphine metabolism is probably crucial. Ratios of morphine to parent drug cannot be used to distinguish the source of morphine after administration of ethylmorphine. Norethylmorphine should be included in urine assays for opiates in forensic toxicology, and no firm conclusions about the source of morphine are possible based on serum samples obtained more than 24 h after drug administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654478      PMCID: PMC1365072          DOI: 10.1111/j.1365-2125.1995.tb05720.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  The metabolic fate of codeine in man.

Authors:  T K ADLER; J M FUJIMOTO; E L WAY; E M BAKER
Journal:  J Pharmacol Exp Ther       Date:  1955-07       Impact factor: 4.030

2.  Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P-450 PCN and interactions with important fetal corticosteroids.

Authors:  M G Ladona; D J Spalding; L Ekman; B Linström; A Rane
Journal:  Biochem Pharmacol       Date:  1989-10-01       Impact factor: 5.858

3.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Authors:  D Paul; K M Standifer; C E Inturrisi; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

4.  Oral morphine in cancer pain: influences on morphine and metabolite concentration.

Authors:  H J McQuay; D Carroll; C C Faura; D J Gavaghan; C W Hand; R A Moore
Journal:  Clin Pharmacol Ther       Date:  1990-09       Impact factor: 6.875

5.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

6.  The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme.

Authors:  M W Coughtrie; B Ask; A Rane; B Burchell; R Hume
Journal:  Biochem Pharmacol       Date:  1989-10-01       Impact factor: 5.858

7.  The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat.

Authors:  A F Sullivan; H J McQuay; D Bailey; A H Dickenson
Journal:  Brain Res       Date:  1989-03-20       Impact factor: 3.252

8.  Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography.

Authors:  J O Svensson; A Rane; J Säwe; F Sjöqvist
Journal:  J Chromatogr       Date:  1982-07-09

9.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

10.  Parameters affecting the yield of DNA from human blood.

Authors:  S Gustafson; J A Proper; E J Bowie; S S Sommer
Journal:  Anal Biochem       Date:  1987-09       Impact factor: 3.365

View more
  1 in total

1.  Predicted Biological Activity of Purchasable Chemical Space.

Authors:  John J Irwin; Garrett Gaskins; Teague Sterling; Michael M Mysinger; Michael J Keiser
Journal:  J Chem Inf Model       Date:  2017-12-29       Impact factor: 4.956

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.